Litcius/Paper detail

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Laura Boekel, Maurice Steenhuis, Femke Hooijberg, Yaëlle R Besten, Zoé L. E. van Kempen, Laura Kummer, Koos P J van Dam, Eileen W Stalman, Erik H Vogelzang, Olvi Cristianawati, Sofie Keijzer, Gestur Vidarsson, Alexandre E. Voskuyl, Luuk Wieske, Filip Eftimov, Ronald van Vollenhoven, Taco W. Kuijpers, S. Marieke van Ham, Sander W. Tas, Joep Killestein, Maarten Boers, Michael T. Nurmohamed, Theo Rispens, Gertjan Wolbink

2021The Lancet Rheumatology172 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)MedicineVaccination2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CohortProspective cohort studyCohort studyVirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisCOVID-19 Clinical Research Studies
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies | Litcius